Contraindications across the group commonly include pregnancy or breastfeeding and being under 18, with additional considerations such as active or recent cancer (CJC + Ipamorelin, IGF-1 LR3), active malignancy (Sermorelin), uncontrolled blood sugar disorders (CJC + Ipamorelin), uncontrolled metabolic or endocrine disorders (IGF-1 LR3, MOTS-C), severe liver or kidney disease (MOTS-C), autoimmune disorders requiring careful metabolic regulation (MOTS-C), and use of insulin or oral hypoglycaemic medications due to hypoglycaemia risk (MOTS-C)
Some research shows that GLP-1s can help lower total testosterone, regulate periods, and even improve spontaneous ovulation rates in women with PCOS
3, 4 June 2022, pp
Manufacturer direct programs and single-use vial options have been introduced to offer lower self-pay alternatives for some doses
PubMed Vukojevic, J., Sikiric, P., et al
However, when combined with another drug called phentermine as the brand-name drug Qsymia, it is FDA-approved as a weight loss medication for: Adults and pediatric patients aged 12 years and older with obesity (a BMI of 30 or greater) Adults who are overweight (a BMI of 27 or greater) and at least one weight-related condition, like type 2 diabetes or high blood pressure It is important to know that Qsymia is classified as a Schedule IV controlled substance